US2020231624A1PendingUtilityA1

Protein purification method

Assignee: CHUGAI PHARMACEUTICAL CO LTDPriority: Sep 11, 2002Filed: Apr 9, 2020Published: Jul 23, 2020
Est. expirySep 11, 2022(expired)· nominal 20-yr term from priority
C07K 1/14C07K 16/00C07K 14/535C07K 1/34C07K 16/26C07K 16/3061C07K 16/065C07K 2317/24C07K 1/30C07K 1/22C07K 16/2866C07K 16/2896
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method is provided for purifying physiologically active proteins, especially antibodies, in order to remove impurities such as DNA contaminants and viruses with minimal loss of physiologically active proteins. The physiologically active protein is introduced into an aqueous solution of low conductivity at a pH of below the isoelectric point of the physiologically active protein to precipitate impurities as particles. The particles are removed, leaving a purified physiologically active protein.

Claims

exact text as granted — not AI-modified
1 - 6 . (canceled) 
     
     
         7 . A method for manufacturing an antibody formulation, which comprises the steps:
 1) applying a composition comprising the antibody and viruses to a protein-A or protein-G affinity column, which binds the antibody,   2) eluting the bound antibody with an aqueous solution of pH of 2.0 to 3.9 and an ionic concentration of 50 mM or less,   3) adjusting the pH of the eluate of step 2) to a pH of from 4.0 to 7.5 by adding a buffer,   4) removing particles comprising the viruses from the eluate of step 3),   thereby obtaining the antibody formulation.   
     
     
         8 . The method according to  claim 7 , wherein the antibody is humanized IL-6 receptor antibody. 
     
     
         9 . The method according to  claim 8 , wherein the antibody is hPM-1 antibody.

Join the waitlist — get patent alerts

Track US2020231624A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.